Skip to main content
. Author manuscript; available in PMC: 2016 Jun 18.
Published in final edited form as: Crit Rev Biochem Mol Biol. 2014 Feb 14;49(2):140–163. doi: 10.3109/10409238.2014.884535

Figure 4.

Figure 4

O-GlcNAc protects against symptoms of neurodegeneration in the Alzheimer’s brain. (A) The microtubule-associated protein Tau can be O-GlcNAc modified at Ser400 and inhibit its subsequent hyperphosphorylation in Alzheimer’s brain samples and models. The nicastrin subunit of the γx secretase complex can also be O-GlcNAcylated at Ser708, preventing APP cleavage and aggregation observed during Alzheimer’s progression. (B) Reducing O-GlcNAc levels on both tau and nicastrin alleviates these protective affects, resulting in neurofibrillary tangles and amyloid β plaque accumulation. (see colour version of this figure at www.informahealthcare.com/bmg).